Cargando…

Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice

BACKGROUND: An effective cancer therapeutic must selectively target tumours with minimal systemic toxicity. Expression of a cytotoxic protein using Salmonella typhimurium would enable spatial and temporal control of delivery because these bacteria preferentially target tumours over normal tissue. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganai, S, Arenas, R B, Forbes, N S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778534/ https://www.ncbi.nlm.nih.gov/pubmed/19861961 http://dx.doi.org/10.1038/sj.bjc.6605403

Ejemplares similares

Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response
por: Venkatasubramanian, R, et al.
Publicado: (2010)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
por: Pukac, L, et al.
Publicado: (2005)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
por: Cantarella, G, et al.
Publicado: (2006)

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
por: Soh, C-L, et al.
Publicado: (2014)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
por: Wang, Y, et al.
Publicado: (2005)

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts
por: Liu, J, et al.
Publicado: (2007)

Soluble tumour necrosis factor receptor type II and survival in colorectal cancer
por: Babic, Ana, et al.
Publicado: (2016)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population
por: Loebinger, M R, et al.
Publicado: (2010)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
por: Marangoni, E, et al.
Publicado: (2009)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines
por: Mahalingam, D, et al.
Publicado: (2009)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt
por: Szegezdi, E, et al.
Publicado: (2006)

Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer
por: Araki, K, et al.
Publicado: (2010)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
por: Hemmerle, T, et al.
Publicado: (2013)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice
por: Bing, C, et al.
Publicado: (2006)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response
por: Yang, Mu-qing, et al.
Publicado: (2018)

A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response
por: Hallac, Rami R, et al.
Publicado: (2016)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice
por: Martikainen, Miika, et al.
Publicado: (2017)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_75bifo7qmothd80g9ib1188453